-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5170d Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Program: Oral and Poster Abstracts
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III
Hematology Disease Topics & Pathways:
Research, Adult, Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Adverse Events, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Hira Shaikh, MD1,2, Jonathan Lochner, PharmD3*, Bradley Loeffler4*, Reed Friend, MD2,5, Alma Habib, MD2,6, Marshall McKenna, MD2,7*, Jordan Snyder, PharmD2,8*, James A Davis, PharmD2,9*, Gina Patrus2,10*, Rachel Dileo2,11*, Prerna Mewawalla12,13*, Kimberly M Green, DO2,9*, Muhammad Umair Mushtaq, MD2,8, Christopher Strouse, MD2,14, Yun Kyoung Tiger, MD, PhD2,7, Al-Ola Abdallah, MD2,15, Nausheen Ahmed, MD2,16, Abdullah Mohammad Khan, MD, MBBS2,6, Hamza Sloan Hashmi, MD9,17,18*, Barry Paul, MD, MS2,5 and Shebli Atrash2,19*

1Division of Hematology, Oncology and Bone Marrow Transplantation, University of Iowa, Coralville, IA
2US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
3Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA
4Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
5Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
6Division of Hematology, The Ohio State University, Columbus, OH
7Division of Hematology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
8Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Overland Park, KS
9Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
10Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA
11Allegheny Health Network Research Institute, Cranberry Twp, PA
12Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA
13US Myeloma Innovations Research Collaborative (USMIRC), kansas city, KS
14Division of Hematology, Oncology, and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
15Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
16Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
17Myeloma Service, Department of Medicine, Memorial Sloan Kettering, New York, NY
18US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, NY
19Levine Cancer, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC

Background: Talquetamab is a G protein-coupled receptor class C group 5 member D (GPRC5D) targeting bispecific T-cell engager (TCE) approved in August 2023 for patients with relapsed-refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy (LOT) including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In this multicenter retrospective study, we evaluated the real-world safety and efficacy of talquetamab in patients exposed to B cell maturation antigen (BCMA) directing therapy.

Methods: Retrospectively, we reviewed electronic medical records of RRMM who received talquetamab monotherapy in five U.S. academic medical centers before 6/1/24. All patients included in the analysis had received at least one full dose of talquetamab. Responses to therapy were evaluated using the International Myeloma Working Group (IMWG) criteria. Adverse events were graded based on the CTCAE v5.0 criteria. Kaplan-Meier methods were used for progression-free (PFS), duration of response (DOR), and overall survival (OS) calculations. Chi-square tests were used to compare responders and non-responders.

Results: Of the total 63 patients (pts) included in this study, 52/63 (83%) were refractory to BCMA directed therapy (BDT). BDT included: CAR-T in 43, TCE in 49, antibody drug conjugate (ADC) in six pts. About half of the patients (31/61) received ≥2 BDT, 29 of these receiving both CAR-T and TCE. BDT was an immediate prior therapy for a significant number of pts (41%, 25/61) and 59% received BDT within 6 months of starting talquetamab.

The cohort received a median of 7 (4–17) prior LOT, most were triple class (87%), penta-drug (68%) refractory, and 46% had extramedullary disease (EMD). Estimated 6-month OS was 75% (95% CI 59-85%) and PFS was 42% (95% CI 27-56%).

Best ORR was the lowest in patients treated previously with ADC (50%) or TCE (59%), when compared to those who had prior CAR-T (72%) or the overall BDT population (68%). In all BDT pts, very good partial response or better (≥VGPR) was observed in 48% while 22% had complete response or better (>CR). There was no statistically significant difference in ORR by CAR-T or ADC exposure, while ORR was lower in pts with prior TCE exposure compared to those without (59% vs 100%, respectively, p<0.01).

BDT as an immediate line was significantly associated with lower ORR (48% vs 81%, p=<0.01) and shorter PFS (HR 2.1, p=0.04). Similarly, BDT within 6 months of talquetamab negatively affected ORR (57% vs 85%, p=0.02), PFS (HR 2.3, p=0.03) and OS (HR 4.8, p=0.04).

Cytokine release syndrome (CRS) was observed in 63% (34/54), with 1 grade III/IV event. Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 13% (7/56), with 1 grade III/IV event. The most common grade III/IV hematological toxicities were thrombocytopenia (24%, 10/42) and anemia (18%, 8/45). Dysgeusia (72%, 39/54), dry mouth (42%, 22/53), weight loss ≥10% (25%, 13/53), nail changes (41%, 21/54), and skin-related events (48%, 25/52) were also noted. Infections occurred in 37% (20/54) of patients, most (70%) involving the respiratory tract.

Conclusion: With the availability of multiple treatment options for RRMM, optimal sequencing of therapies is a challenging question. Our data shows that talquetamab conferred high responses in patients previously treated with BDT. However, in this cohort of pts, the immediate prior use of BDT, particularly within 6 months of talquetamab was associated with inferior outcomes.

Disclosures: Davis: Janssen Biotech: Speakers Bureau. Strouse: Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; Bristol Meyer Squibb: Research Funding; Seagen: Research Funding; Poseida: Research Funding. Ahmed: Legend Biotech: Consultancy, Honoraria; Kite/Gilead: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Khan: Amgen: Speakers Bureau; Sanofi: Research Funding, Speakers Bureau; BMS: Research Funding, Speakers Bureau. Paul: Regeneron Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding; AbbVie Inc: Membership on an entity's Board of Directors or advisory committees; Johnson & Johnson: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH